Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

× No keyword cloud information.

35 in total

Review 1. [Multiparametric MRI, elastography, contrastenhanced TRUS. Are there indications with reliable diagnostic advantages before prostate biopsy?].

Authors: A Hegele; L Skrobek; R Hofmann; P Olbert
Journal: Urologe A Date: 2012-09 Impact factor: 0.639

2. Evidence based radiation oncology with existing technology.

Authors: Nicolas Isa
Journal: Rep Pract Oncol Radiother Date: 2013-10-14

3. Double-blind, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-683, an investigational metastin analogue in healthy men.

Authors: Graham Scott; Irfan Ahmad; Katy Howard; David MacLean; Cristina Oliva; Steve Warrington; Darren Wilbraham; Paul Worthington
Journal: Br J Clin Pharmacol Date: 2013-02 Impact factor: 4.335

4. Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer.

Authors: Lesley J Scott; Lily P H Yang; Katherine A Lyseng-Williamson
Journal: Drugs Aging Date: 2012-03-01 Impact factor: 3.923

5. Abiraterone acetate: in metastatic castration-resistant prostate cancer.

Authors: Lily P H Yang
Journal: Drugs Date: 2011-10-22 Impact factor: 9.546

6. Differences in practice patterns between urologists and radiation oncologists in the management of localized prostate cancer: a cross-sectional survey.

Authors: Mehdi Mokhtar Ariane; Guillaume Ploussard; Xavier Rebillard; Bernard Malavaud; Pascal Rischmann; Christophe Hennequin; Pierre Mongiat-Artus
Journal: World J Urol Date: 2015-03-31 Impact factor: 4.226

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Review 1. [Multiparametric MRI, elastography, contrastenhanced TRUS. Are there indications with reliable diagnostic advantages before prostate biopsy?].

2. Evidence based radiation oncology with existing technology.

3. Double-blind, randomized, placebo-controlled study of safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-683, an investigational metastin analogue in healthy men.

4. Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer.

5. Abiraterone acetate: in metastatic castration-resistant prostate cancer.

6. Differences in practice patterns between urologists and radiation oncologists in the management of localized prostate cancer: a cross-sectional survey.

Review 7. Optimal management of cancer treatment-induced bone loss: considerations for elderly patients.

8. Differences in inherited risk among relatives of hereditary prostate cancer patients using genetic risk score.

9. Healthcare Funding Decisions and Real-World Benefits: Reducing Bias by Matching Untreated Patients.

10. Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands.